May 9, 2012
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2012 Results

May 1, 2012
Bioniche Life Sciences Inc. Commercializing Two Products for Canine Cancer

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Latest ASX stock price

All prices delayed at least 20 minutes.
Source: ASX Inc.

Bioniche Life Sciences Inc. is a leading, fully-integrated biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. 

The information contained in the Company’s news releases was accurate at the time of posting on this website, but the information may be superseded by subsequent corporate disclosures.

Media Coverage

For recent media coverage of Bioniche Life Sciences Inc. click here >>

Latest News

May 9, 2012
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2012 Results more...

May 1, 2012
Bioniche Life Sciences Inc. Commercializing Two Products for Canine Cancer more...

April 18, 2012
Bioniche Life Sciences Inc. Sponsors Two Major International Livestock Reproduction Conferences more...

Shareholder Newsletter

April, 2012 Newsletter

More News

Bioniche Key Facts

Founded: 1979

Chairman, President & CEO:
Graeme McRae

TSX stock symbol:
 

Fiscal year-end:
June 30

2010 revenues:
C$46 million

Headquarters:
Belleville, Ontario

Employees worldwide:
228

Business divisions:
Human Health,
Animal Health,
Food Safety

Focus areas:
Human Health:
cancer, immunomodulation

Animal Health:
reproduction, vaccines, replacement of antibiotics

Food Safety: E. coli O157 vaccine, other veterinary biopharmaceutical products to address diseases in livestock which may have an effect on human health

Top products:

Animal Health:
Folltropin®-V, MAP®-5